PPCB (NASDAQ:PPCB) Issues Earnings Results

PPCB (NASDAQ:PPCB) posted its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, FiscalAI reports.

PPCB Price Performance

NASDAQ PPCB traded down $0.02 during trading hours on Thursday, reaching $0.07. 3,387,197 shares of the company traded hands, compared to its average volume of 1,566,648. PPCB has a 12 month low of $0.07 and a 12 month high of $10.81. The stock has a 50 day simple moving average of $0.11.

PPCB’s stock is scheduled to reverse split before the market opens on Monday, May 18th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, May 17th.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised PPCB from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

PPCB Company Profile

Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.